Danese S, Panaccione R, D’Haens, et al. Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with moderately to severely active ulcerative colitis: 12-week results from the phase 2 LATTICE-UC study. The gene discussed is TYK2; the disease is ulcerative colitis.